Publications

PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose. Jimmy A Rotolo, Ricardo A. Ramirez, Raymond Schuch, Matthias Machacek, Tatiana Khariton, Parviz Ghahramani, and Michael Wittekind. ASM Microbe 2016, June 18.

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek, Lionel Renaud, Sasa Dimitrijevic, Debora Schmitz, Elena Ivanova, Karin Jorga. J Clin Oncol 34, 2016 (suppl; abstr e14101).

Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen. J Clin Oncol 34, 2016 (suppl; abstr e15602).